B-cell lymphomas often develop in the central nervous system (CNS). Although rituximab (RTX) has been widely used for most B-cell lymphomas, the efficacy for CNS lymphomas has yet to be elucidated.
7 centrifuged and the supernatant was removed, the cell pellet was loosened by tapping, aspirated into a microinjector, and left on ice until inoculation. A 5-μL aliquot of this pellet, which contained 1  10 6 to 3
 10 6 cells, was inoculated into the deep frontal lobe of the cerebrum of the above-prepared nude rats at 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8 FITC-conjugated rabbit immunoglobulin. Rats administered control immunoglobulin and human serum were stained in the same manner as negative controls. After rinses, the samples were covered with VECTASHIELD Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA) and observed with an Axioplan2 fluorescent microscope (Carl Zeiss, Oberkochen, Germany). Images were taken and analyzed with an AxioCam CCD camera and AxioVision4.6 image processing software (Carl Zeiss), respectively.
Treatment of lymphomas in CNSL model rats
Once a day on day 5 through day 9 after Raji innoculation, CNSL model rats were intraventricularly administered with a mixture of 100 μg (10 μL) of RTX or control immunoglobulin with 10 μL of human serum, or a mixture of the same dose of RTX with saline. The survival data were collected from 10 independent experiments. The rats were observed and weighted once a day after intraventricular administration. When >25% weight reduction or obvious weakness was observed, the rat was euthanized, and this time point was defined as the end of survival. The brains were removed from all of the rats, regardless of whether death was natural or by euthanasia. If no lymphoma was found in the brain, the animal was excluded from the analysis. Survival of each group was analyzed with the Kaplan-Meier method and log-rank test with StatCell version 2 software (OMS, Saitama, Japan), and (Fig. 4 , lower panels). This demonstrates that intraventricular RTX penetrated the ependymal layer and brain parenchyma, and finally reached and bound to lymphoma cells.
To evaluate the anti-lymphoma effect of intraventricular RTX and serum, the tumor-inoculated rats were treated with either RTX plus serum, RTX plus saline, or control immunoglobulin plus serum.
Lymphoma development was confirmed histologically in all the rats examined. A single rat in the RTX-plus-serum group died from technical error during the treatment period and was excluded from this analysis. The RTX-plus-serum group survived significantly longer than the control-immunoglobulin-plus-serum group (P = 0.049; Fig. 5 ). The RTX-plus-serum group also appeared to survive longer than the RTX-plus-saline group, although the difference was not statistically significant (P = 0.083). The survival times of the RTX-plus-saline and control-immunoglobulin-plus-serum groups did not differ from each other (P = 0.382). Body weights transiently decreased immediately after the intraventricular treatment in all arms, but all the rats subsequently re-gained the weight, which began to decrease shortly before the death (Supplemental Fig.   1 ). 
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